Comparison of immunohistochemistry

Background The concordance rate between IHC and FISH according to clinical performance is still controversial. We report a prospective study to reflect the concordance between IHC and FISH in Guilin city, People's Republic of China. Methods Fifty cases of invasive ductal carcinoma of breast tes...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of surgical oncology Vol. 7; p. 83
Main Authors Chen, Jiejing, Ou, Minglin, Sui, Weiguo, Qi, Minfang, Huang, He, Wan, Youhua, Peng, Hongbo, Dai, Yong
Format Journal Article
LanguageEnglish
Published BioMed Central Ltd 09.11.2009
Subjects
Breast cancer
Comparative analysis
Drug therapy
Health aspects
Immunohistochemistry
In situ hybridization
Methods
China
Online AccessGet full text

Cover

More Information
Summary:Background The concordance rate between IHC and FISH according to clinical performance is still controversial. We report a prospective study to reflect the concordance between IHC and FISH in Guilin city, People's Republic of China. Methods Fifty cases of invasive ductal carcinoma of breast tested by IHC and scored as 0, 1+, 2+ and 3+ by pathologists were further analyzed by FISH using a commercially available double-color probe, and the FISH findings were compared with IHC test results. Results A total concordance of 82.0% was observed with a Kappa coefficient of 0.640 (P [less than] 0.001). A high discordance was observed in 30.0% of the patients with IHC 2+, 7.1% in IHC 3+, 19.2% overall in IHC 0 and 1+. Conclusion The IHC can be used firstly to screen the HER-2 status, and FISH can be used as a supplementary role to IHC and 2+ and some negative cases. And only those cases with Her-2 status of IHC 3+ or FISH positive should be treated with Herceptin.
ISSN:1477-7819
1477-7819